Track the LIGAND PHARMACEUTICALS INCORPORATED share price and the full management transaction log of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €5.7bn. The latest transaction was filed on 10 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: ANDREW REARDON. The full history is free.
8
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate LIGAND PHARMACEUTICALS INCORPORATED Strong Buy (bullish), based on 11 analysts. Average price target: US$342.82.
33Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 11,203 of 29,064 companies
57.3
score / 100
Value
33
Quality
82
FCF yld0.7%
Earn yld2.2%
EV/EBITDA31.0x
ROE22%
Gross mgn95%
Net mgn46%
Debt/EBITDA2.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.